NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting

Stock Information for NervGen Pharma Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NervGen Pharma Corp.

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Canadian Investment Regulatory Organization Trade Resumption - NGEN
Canadian Investment Regulatory Organization Trading Halt - NGEN
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.